Brief: Achieve Life Sciences Says Cytisinicline NDA Submission To FDA Planned For June 2025
21/04/2025 18:47
April 21 (Reuters) - Achieve Life Sciences Inc ACHV.O: ACHIEVE LIFE SCIENCES ANNOUNCES CYTISINICLINE PHASE 3 ORCA-3 TRIAL PUBLICATION ON SMOKING CESSATION IN JAMA INTERNAL MEDICINE ACHIEVE LIFE SCIENCES INC - CYTISINICLINE NDA SUBMISSION TO FDA PLANNED FOR JUNE 2025 Source text: ID:nGNX6nrvpC Further company coverage: ACHV.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Achieve Life Sciences
See all newsAchieve Life Sciences Q3 net loss and loss per share beat estimates
Brief: Achieve Life Sciences Presents 52-Week Cytisinicline Results For Smoking And Vaping Cessation At Chest 2026
Brief: Lisata Therapeutics Appoints Jeff Farrow To Board Of Directors
Brief: Achieve Life Sciences Appoints Kaitlyn Tuson As Senior Vice President, Marketing And Communications
Brief: Achieve Life Sciences - Enters ATM Sale Agreement With Jefferies For Up To $150 Million In Common Stock